$24.52
-0.94-3.69%
In chiusura: -
$24.35
-0.17-0.69%
After hour: Oct 10, 7:59 PM EDT
Intellia Therapeutics segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Analizza lo storico degli utili di Intellia Therapeutics utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
NTLA | Intellia Therapeutics | -$1.34 | -$0.99 | — | — | $9.11M | $14.19M | — | — | 11/06/2025 | |
NTLA | Intellia Therapeutics | -$1.52 | -$1.02 | -$0.98 | 3.92% | $6.96M | $12.51M | $14.24M | 13.91% | 08/07/2025 | |
NTLA | Intellia Therapeutics | -$1.12 | -$1.27 | -$1.10 | 13.39% | $28.93M | $11.99M | $16.63M | 38.67% | 05/08/2025 | |
NTLA | Intellia Therapeutics | -$1.46 | -$1.32 | -$1.27 | 3.79% | -$1.92M | $8.10M | $12.87M | 58.94% | 02/27/2025 | |
NTLA | Intellia Therapeutics | -$1.38 | -$1.38 | -$1.34 | 2.90% | $11.99M | $7.86M | $9.11M | 15.92% | 11/07/2024 | |
NTLA | Intellia Therapeutics | -$1.40 | -$1.23 | -$1.52 | -23.58% | $13.59M | $19.16M | $6.96M | -63.69% | 08/08/2024 | |
NTLA | Intellia Therapeutics | -$1.17 | -$1.38 | -$1.12 | 18.84% | $12.61M | $11.50M | $28.93M | 151.61% | 05/09/2024 | |
NTLA | Intellia Therapeutics | -$1.40 | -$1.45 | -$1.46 | -0.69% | $13.57M | — | -$1.92M | — | 02/22/2024 | |
NTLA | Intellia Therapeutics | -$1.49 | -$1.50 | -$1.38 | 8.00% | $13.27M | $12.45M | $11.99M | -3.68% | 11/09/2023 | |
NTLA | Intellia Therapeutics | -$1.33 | -$1.32 | -$1.40 | -6.06% | $14.03M | $13.95M | $13.59M | -2.55% | 08/03/2023 | |
NTLA | Intellia Therapeutics | -$1.96 | -$1.40 | -$1.17 | 16.43% | $11.25M | $11.83M | $12.61M | 6.56% | 05/04/2023 | |
NTLA | Intellia Therapeutics | -$1.09 | -$1.39 | -$1.40 | -0.72% | $12.85M | $11.33M | $13.57M | 19.80% | 02/23/2023 | |
NTLA | Intellia Therapeutics | -$0.97 | -$1.28 | -$1.49 | -16.41% | $7.20M | $11.31M | $13.27M | 17.29% | 11/03/2022 | |
NTLA | Intellia Therapeutics | -$1.01 | -$1.31 | -$1.33 | -1.53% | $6.55M | $9.42M | $14.03M | 48.94% | 08/04/2022 | |
NTLA | Intellia Therapeutics | -$0.69 | -$1.10 | -$1.96 | -78.18% | $6.45M | $8.54M | $11.25M | 31.76% | 05/05/2022 | |
NTLA | Intellia Therapeutics | -$0.69 | -$0.94 | -$1.09 | -15.96% | $6.59M | $8.26M | $12.85M | 55.62% | 02/24/2022 | |
NTLA | Intellia Therapeutics | -$0.47 | -$0.84 | -$0.97 | -15.48% | $22.22M | $8.66M | $7.20M | -16.81% | 11/04/2021 | |
NTLA | Intellia Therapeutics | -$0.61 | -$0.63 | -$1.01 | -60.32% | $16.26M | $11.89M | $6.55M | -44.91% | 08/05/2021 | |
NTLA | Intellia Therapeutics | -$0.63 | -$0.67 | -$0.69 | -2.99% | $12.92M | $8.57M | $6.45M | -24.80% | 05/06/2021 | |
NTLA | Intellia Therapeutics | -$0.57 | -$0.60 | -$0.69 | -15.00% | $10.94M | $14.09M | $6.59M | -53.19% | 02/25/2021 | |
NTLA | Intellia Therapeutics | -$0.49 | -$0.59 | -$0.47 | 20.34% | $10.62M | $15.58M | $22.22M | 42.62% | 11/05/2020 |
Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
---|---|---|---|---|
Q2 | 2025-08-07 | $-0.98 | $-1.02 | 3.92 % |
Q1 | 2025-05-08 | $-1.10 | $-1.27 | 13.4 % |
Q4 | 2025-02-27 | $-1.27 | $-1.32 | 3.79 % |
Q3 | 2024-11-07 | $-1.34 | $-1.38 | 2.90 % |
Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
---|---|---|---|---|
Q2 | 2025-08-07 | $14.25M | $12.51M | 13.9 % |
Q1 | 2025-05-08 | $16.63M | $11.99M | 38.7 % |
Q4 | 2025-02-27 | $12.87M | $8.10M | 58.9 % |
Q3 | 2024-11-07 | $9.11M | $7.86M | 15.9 % |
Si prevede che Intellia Therapeutics (NTLA) fornisca risultati il novembre 6, 2025. Gli ultimi risultati sono stati pubblicati il agosto 7, 2025 per il Q2.
L'EPS effettivo era $-0.98, che superato la stima di $-1.02.
Le entrate effettive sono state $14.2M, che superato la stima di $12.5M.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.